SUBJECT INDEX

Acamprosate, 669
Acetaminophen, 189
Acetylcholine (ACh), 23, 529, 637, 841
ACh level, 99
Acquisition, 211
Active avoidance, 445, 837
Activity, 581, 587
Acute, 409
Acute exercise, 773
Added point loss, 139
Addiction, 219
Adrenalectomy, 599
Adverse side effects, 567
Aging, 611
Agonist, 219
Alarm cries, 551
Alarm substance, 599
Albuterol, 483
Alcohol, 49, 105, 127, 133, 355, 587, 795
Alcohol intake, 105
Alcohol-related birth defects, 587
Alcohol sensitivity, 795
N-Allylnormetazocine, 215
α_2-Adrenergic receptors, 267
α_2-Receptor localization, 267
α_2-Receptor subtypes, 267
α_{2A}, 267
α_{2B}, 267
Alphaxalone, 399
Alprazolam, 425
Amnesia, 715
Amnestic agents, 761
Amphetamine, 29, 203, 259, 309, 837
d-Amphetamine, 283, 391, 859
Amygdala, 109, 115, 121, 127
Analgesia, 53, 65, 153, 449, 665
Androgen-dependent behavior, 195
Angiotensin converting enzyme inhibitor, 105
Angiotensin II, 105
Angiotensin II-induced drinking, 183
Antagonism, 245, 529
Antagonist, 219
Anticonvulsant, 109, 115, 121, 127, 789
Antihypertensive agents, 567
Antinociception, 53, 65, 371, 429
Antipredator defense, 551
Antistereotypic activity, 665
Antitussive mixture, 783
Anxiety, 551, 643, 683, 719
Anxiolytic, 13, 405, 475, 573
Anxiolytic effect, 425
Apomorphine, 171, 177, 511
Arginine vasopressin, 409
Aromatization, 733
Atipamezole, 611
Atropine, 377
Attention, 195
Autoreceptor, 841
Avoidance behavior, 145
Avoidance schedule, 139
Azaprophen, 377

Baboons, 567
Baclofen, 651, 695
Barbital, 795
Barbiturates, 355
Basal ganglia, 547
Behavior, 219, 321, 461, 719
Behavioral CRs, 239
Behavioral effects, 377
Behavioral satiety sequence, 801
Behavioral sensitization, 841
Behavioral tolerance, 121, 127, 133
Benactyzine, 377
Benzodiazepine inverse agonist, 455
Benzodiazepine receptor ligands, 859
Benzodiazepines, 355, 405, 461, 475, 529, 719
β_2 adrenoreceptors, 483
Bicuculline, 727
Blood-brain barrier, 255
Blood glucose, 295
Blood pressure, 567
BMY-14802, 29, 215
Bone, 289
Brain, 539
Brain ^{3}H-2-deoxyglucose uptake, 295
Brain glucose, 295
Brain lesions, 727
Brain self-stimulation, 391
Brain-stimulation reward, 755
Buspirone, 573

Caffeine, 659, 783
Calcium channel blocking agents, 567
Calcium uptake, 695
Cannabinoids, 469
Carbamazepine, 109, 115, 121, 813
Carbon monoxide, 749
Catalepsy, 301, 547
Catecholamines, 195, 329, 733, 739
Cathinone, 37
Central neurotransmission, 445
Central receptors, 461
Cerebellum, 761
CGS 10746B, 37, 807
Chemical and electric seizures, 99
Chick, 761
Chickens, 349
Chlordiazepoxide, 475, 529, 643
Chlorpheniramine, 783
1-(*m*-Chlorophenyl)biguanide, 361
m-Chlorophenylpiperazine, 621
Chlorpromazine, 13
Choice, 817
Choice measures, 825
Cholecystokinin, 83
Cholinergic, 23, 547, 625
Cholinergic function, 433
Cholinergic systems and memory, 715
Cholinesterase in RBC and tissues, 773
Cholinesterase inhibitor, 251
Chronic, 409
Chronic ethanol, 275
Chronic intoxication, 49
Cigarette smoke, 655
Cigarette smoking, 749
cis-Flupenthixol, 489
Classical conditioning, 239
Clonazepam, 115
Clonidine, 153, 519
Clozapine, 29
Cobalt epilepsy, 813
Cocaine binding, 227
Cocaine extinction responding, 415
Cocaine methiodide, 851
Cocaine, 219, 227, 283, 365, 377, 415, 497, 519, 643, 659, 837, 841, 851
Cocaine-maintained responding, 415
Codeine, 349
Cognition, 159
Cold exposure, 795
Conditioned avoidance response, 29
Conditioned drug effects, 239
Conditioned flavor aversions, 239
Conditioned food aversions, 239
Conditioned place preference, 817, 825
Conditioned taste aversion, 43, 239, 245, 455, 559
Conditioned withdrawal, 543
Conditioning, 13
Conflict, 399
Conflict behavior, 651
Conspecific odors, 581
Consummatory acts, 251
Contingent tolerance, 121, 127, 133
Continuous reinforcement, 309
Convulsions, 109, 115, 121, 127, 133, 159, 599
Copulation, 133
Cortex, 317, 675
Corticosterone, 317, 643, 795
Corticotropin releasing factor, 399
Cotinine, 701
CQ 32-084, 683
Cross tolerance, 115, 127, 355
Cue learning, 529
Cumulative dosing, 83, 365
Curiosity, 625
CY 208-243, 511

D_1 dopamine receptors, 235
D_1 receptors, 321, 343
D_2 agonist, 65
D_2 autoreceptors, 683
D_2 receptors, 259, 343, 841
d-Amphetamine, 283, 391, 859
DADL ([D-Ala^2, D-Leu^5]enkephalin), 171
Defensive withdrawal, 643
Delayed spontaneous alternation response, 573
Delta-amino-*n*-valeric acid, 651
2-Deoxy-D-glucose, 371
Dependence, 49
Depression, 23
[Des-Gly^9,d(CH$_2$)$_5^1$,O-Et-Tyr^2,Val^4,Arg^8]-vasopressin, 409
Detection threshold, 391
Development, 69, 469
Dextromethorphan, 215
Diabetes, 483
Diazepam, 1, 13, 109, 121, 159, 461, 573, 695, 859
Diazepam withdrawal, 695

Differential conditioning, 333
Differentiation, 69
Dihydrocodeine, 783
Dipsogenic agent, 183
Discriminative stimulus effects, 377
Discriminative stimulus properties, 391
Ditolyguanidine, 215
DN-2327, 573
DOCA-salt hypertension, 567
DOI, 519
Domestic fowl, 349
Domoic acid, 211
DOPAC, 469
Dopamine, 37, 57, 75, 177, 231, 343, 469, 489, 501, 511, 607, 643, 675, 683, 807, 841
Dopamine autoreceptors, 227
Dopamine D_1 antagonist, 507
Dopamine metabolism, 301
Dopamine receptors, 343
DPLPE ([D-Pen^2, L-Pen^5]enkephalin), 171
Drinking, 847
Drug dependence, 219
Drug discrimination, 43, 165, 245, 321, 361, 783, 789
Drug discrimination learning, 245
Drug interaction, 83, 405, 659
Drug kinetics, 489
Drug reinforcement, 559, 825
Drug tolerance, 133
DSP-4, 195

ECoG, 813
Edema, 53
EEDQ, 321
Electrical resistance, 855
Electroconvulsive shock, 663
Elevated plus-maze, 643
Elevated plus-maze test for anxiety, 91
Eltoprazine, 801
Eltoprazine hydrochloride (DU 28853), 581
Emesis, 215
Endorphins, 559
Endurance-trained exercise, 773
Enhancement of memory, 295
Enrichment, 689
Entorhinal cortex, 767
Estrogen, 255
Estrous, 153, 719
Ethanol, 127, 133, 189, 263, 409, 455, 587, 663, 669, 689
Ethanol intake, 385, 847
Ethyl acetate, 79
Experimental hypocholinergic model, 433
Exploration, 625
Exploratory behavior, 91
Extinction, 847
Extrahypothalamic, 329, 733

False precursor (NADe), 433
False transmitter, 433
Fasciculin, 547
Fear, 551
Feather, 289
Feed behavior, 683
Femoxetine, 801
Fentanyl, 615
Fetal Alcohol Syndrome, 587
FI60, 475
FI behavior, 659
Filter perforation, 749
Fixed-interval schedules, 377
Fixed-ratio schedule, 83
Flinders Sensitive Line, 23
Fluid exchange, 183
Flumazenil, 529
cis-Flupenthixol, 489
Follicle stimulating hormone, 255
Food intake, 7, 385
Food-maintained responding, 415
Foot-shock, 317
Four plates test, 405
FR/DRL schedule, 251
Frontal cortex, 637

GABA, 1, 49, 405, 501, 603, 651
GABA levels, 99, 669
GABA-T inhibitors, 603
$GABA_A$ receptors, 767
Gender differences, 153
Generalization, 43
Genetic model, 795
Gerbils, 231, 539
Glucose, 65
Glucose + saccharin-maintained responding, 415
L-α-Glycerylphosphorylcholine, 445
Glycine, 263
Gonadectomy, 153
Grooming, 385, 683
Growth hormone, 795
Gulls, 289

H_2 receptor, 371
[^{3}H]-5-HT release, 695
^{3}H-GABA uptake, 669
Haloperidol, 13, 29, 177, 215, 301, 547
Haloperidol decanoate, 13
Hamsters, 543
Hemispheric asymmetry, 761
n-Hexane, 79
Hippocampus, 211
Histamine, 371
Histamine-receptor, 317
Homotaurine, 49
Hot-plate, 449
5-HT, 53, 91
5-HT antagonists, 53
5-HT receptors, 53, 429, 621
5-HT uptake inhibitors, 801
5-HT_1 receptors, 801
5-HT_{1A}, 5-HT_{1B}, and 5-HT_{1C} receptors, 519
5-HT_2 antagonist, 241
5-HT_3, 361
5-HT_3 antagonists, 659
5-HT_3 receptors, 807, 847
Human, 139
HVA, 547
HVS, PA, and WM performance, 611
Hydrochlorothiazide, 567
6-Hydroxydopamine, 343, 621
Hyperactivity, 501, 603
Hyperalgesia, 349
Hyperglycemia, 65
Hyperhydration, 183
Hyperphagia, 371
Hypoalgesia, 349

Ibotenic acid, 607
ICS 205-903, 37
ICS 205-930, 361, 519
Idazoxan, 267, 707
IMHV, 761
Imipramine, 599
Immobility, 425, 507
Inclined plane, 13
Individual differences, 203
Inferior colliculus, 727
Inflammation, 53
Ingestive behavior, 483
Intake, 689
Interactions, 13
Intermediate-term memory, 761
Intracerebral microinjection, 727
Intracerebroventricular, 409
Intraventricular, 329, 733
Investigatory behavior, 625
Ischemia, 231
Isradipine, 37, 497, 807

Ketanserin, 53
Ketocyclazocine, 7
Kindling, 109, 115, 121, 127

L-α-Glycerylphosphorylcholine, 445
Latency, 817, 825
Lead, 289
Learning, 211, 587, 625
Learning and memory, 445, 573
Lever release, 29
LHRH agonist, 665
LHRH antagonist, 665
Lidocaine, 851
Limited access procedure, 385
Lisuride, 683
Lithium, 239
Liver, 289
Locomotion, 91, 227, 301, 607
Locomotor activity, 171, 203, 251, 365, 377, 391, 655
Long-term memory, 761
Lorazepam, 659, 795
LPO, 761
LS and SS mice, 275
Luteinizing hormone, 255, 795
Luteinizing hormone-releasing hormone, 255, 665
LY-171555, 177

1-(*m*-Chlorophenyl)biguanide, 361
m-Chlorophenylpiperazine, 621
Magnesium chloride, 415
Magnesium-deficient diet, 415
Male sexual behavior, 511, 739
Masculinization, 329
Matching-to-sample, 283
mCPBG, 519
MDA, 333
MDL 72222, 37
Mecamylamine, 755
Median raphe nucleus, 501
Melatonin, 405
Memory, 1, 625, 761, 851
Memory consolidation, 767
Memory modulation, 837
Memory retrieval, 145
Methamphetamine, 783
Methylephedrine, 783
2-Methylserotonin, 361
Methysergide, 53
Metoclopramide, 177
Mice, 171, 211, 301, 365, 429, 851, 855
Mifepristone, 69
Milacimide, 263
Minaprine, 715

Modified forced-swim test, 425
Monoamine levels, 655
Monoamines, 231
Morphine, 83, 245, 449, 497, 543, 551, 615, 727, 825
Morris water maze, 211, 529
Motor behavior, 75, 567, 707
Mouse striatum, 227
Moving belt, 409
Multitrial, 715
Muscimol, 49, 501
Mussel toxin, 211
Myorelaxant, 13

N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl) acetamide (DM-9384), 231
N-Allylnormetazocine, 215
n-Hexane, 79
Naloxone, 245, 349, 475, 543, 755
Naloxone-precipitated withdrawal, 543
Naltrexone, 559
Naturalistic environment, 701
Neonatal, 69, 329
Neostriatum, 675
Nerve agents, 159
Neuroexcitant amino acid, 211
Neuroexcitotoxin, 211
Neuromotor development, 587
Neurotensin, 385
Neurotoxin, 211
Neurotransmitter system preceptors, 539
Nicotine, 23, 57, 139, 219, 701, 749, 755, 807
Nicotine abstinence, 139
Nictitating membrane response, 333
Nimodipine, 497
Nitrous oxide, 429
NMDA receptors, 263, 767
Nociception, 53
Nomifensine, 391
Nonhuman primates, 567
Noradrenaline, 231
Noradrenergic system, 739
Norepinephrine, 195, 675
Novel odors, 581
Novelty, 203
Nucleus accumbens, 57, 177, 203, 501
Nucleus basalis, 637
Nucleus basalis magnocellularis, 445

Odansetron, 53
Oestrous, 719
8-OH-DPAT, 519
Olfactory preference, 581
One-way active avoidance, 851
Ontogeny, 621
Open field, 733
Open-field behavior, 675
Operant behavior, 251
Opiate antagonists, 43, 559
Opiate withdrawal, 543
Opiates, 349, 559
Opioid, 219, 349
Opioid receptor, 65
Oral dyskinesia, 621
Organic solvents, 79
Organophosphate, 159
Oxytocin, 7

P and NP rats, 105
Pain, 53, 349
Palatability, 559
Para-aminoclonidine, 267
Para-ethoxyamphetamine, 165
Para-methoxyamphetamine, 165
Paracetamol, 189
Paroxetine, 801
Partial reinforcement, 309
Passive avoidance, 445, 573
Passive avoidance tests, 715
Pattern recognition, 707
Paw pad, 855
Penile erection, 511
Pentobarbital, 127, 283
Periaqueductal gray, 727
Peripheral type receptors, 461
Phencyclidine, 83, 283, 603
Phenobarbital, 115
Phlorizin, 295
Physostigmine, 529, 773
Pigeons, 83, 283
Pilocarpine, 153
Pimozide, 13, 301, 489
Place conditioning, 559, 817, 825, 859
Place learning, 529
Place task, 211
Play, 817
Plus maze, 13, 399
Posttraining, 837
Posttraining memory processing, 767
(+)-3-PPP, 215
Prefrontal cortex, 607
Prepregnancy, 587
Primates, 511
Proactive interference, 283
Progesterone, 69, 255
Progressive degenerative dementia, 433
Prolactin, 795
Prostaglandin inhibitors, 189
Psychopharmacology, 239
Puff-by-puff analysis, 701
Pulmonary alcoholization, 669
Pyridostigmine, 251

Q-ICS 205-930, 361
Quinelorane, 511
Quinpirole, 65

Rabbit, 333
Radioimmunoassay, 719
Rapid tolerance, 355
Rate of decarbamylation, 773
Rats, 23, 37, 49, 53, 99, 109, 115, 121, 127, 133, 153, 203, 241, 317, 355, 371, 377, 409, 415, 461, 475, 507, 511, 529, 539, 573, 587, 607, 655, 675, 707, 783, 801, 807, 813, 817, 825, 837
Rattus norvegicus, 625
Rauwolscine, 267
Rearing, 655
Receptor autoradiography, 539
Red nucleus lesions, 99
Reflex modification, 333
Regulation, 219
Reinforcement, 165, 219, 489
Remoxipride, 259
Renin-angiotensin system, 105
Renovascular hypertension, 567
Resistance to extinction, 309
Respiration, 349
Resting, 385
Restraint stress, 449
Restricted access, 847
Reward, 489, 859
Rhesus monkeys, 159, 235, 511
Ritanserin, 241
Ro 15-1788, 859
Ro 15-4513, 455
Ro 16-6028, 859
(R/S)-4-VinylGABA, 603
RU 486, 69

(S)-4-AllenylGABA, 603
SCH 23390, 177, 321, 507
SCH 39166, 235
Scopolamine, 529, 625, 715, 855
Seizure, 109, 115, 121, 127, 263, 365, 663
Self-administration, 165, 219, 259, 415, 615, 789
Self-administration by naive mice, 497
Self-stimulation, 489, 755
Sensitization, 203, 275, 365
Septum, 675
Serial probe recognition (SPR), 159
Serotonin, 53, 231, 241, 329, 501, 643, 675, 733, 789
Sertraline, 789
Sex differences, 551
Sexual behavior, 69, 91, 133, 329, 733
Sexual behavior and orientation, 91
Sexual differentiation, 91, 733
Sexual hormones, 329
Shock-induced fighting, 49
Short-term memory, 761
Sigma site, 215
Single cigarette, 701
SK&F 38393, 177, 321
SK&F 83566, 507
Sleep, 241
Smoking, 701
Social reinforcement, 817
Sodium valproate, 109, 121
Solvents and convulsions, 79
Soman, 159
SP(1-7), 75
Spatial discrimination, 817
Spatial learning, 1, 637
Spatial navigation, 211
SQ 29,852, 105
Stereotypic behavior, 343
Stereotypy, 29
Steroids, 399
Stimulus properties of drugs, 37, 807
Straw-climbing behavior, 425
Straw suspension, 425
Stress, 317, 399, 587, 599, 607, 615, 663
Striatum, 203
Subcutaneous, 409
Submissive odors, 581
Substance P, 75
Substantia nigra, 75
Successive discrimination, 475
Sulpiride, 29, 301
Supersensitivity, 343, 519
Supersensitization, 621
Sustained release, 219
Swim, 607

Tail-flick, 449
Tail suspension test, 405
Taste conditioning, 559
Taste reactivity, 559
Taste reactivity test, 239
Testosterone, 255
TFMPP, 519
THA, 637

Thalamus, 675
Thermal nociception, 349
Thermoregulation, 23
Thiazide diuretics, 567
Thioridazine, 13
Thyrotropin, 795
Thyroxine, 145
Tissue deposition, 289
Titration schedule, 283
Tobacco abstinence, 139
Tobacco administration, 139
Tobacco smoke exposure reduction, 749
Tolerance, 109, 115, 121, 127, 275, 409
Toluene, 79
Toxin, 547
TRH, 145
Triiodothyronine, 145
Trimethadione, 115
Turning, 177
Tyrosine hydroxylase, 469

Ultrasonic vocalization, 551
Up-regulation, 235

Vaginal opening, 69
Valproic acid, 109, 121
Vasopressin, 7, 409
Ventral mesencephalon, 675
Verapamil, 567
Vigabatrin, 603
Visual discrimination, 251
Vocal control system, 195
Vocalizations, 739

Waking, 241
Water, 817
Water intake, 251, 385, 847
Wet-dog shakes, 99
Wild running, 727
Withdrawal, 49

X-maze, 683

Yohimbine, 267, 707

Zacopride, 847
Zolantidine, 371

AUTHOR INDEX

Abel, E. L., 599
Airaksinen, M. M., 701
Alburges, M. E., 267
Allen, R. P., 567
Alvares, K., 615
Ambrogi Lorenzini, C., 715
Amit, Z., 259
Ando, K., 783
Andrews, N., 695
Araki, T., 539
Araki, Y., 655
Arolfo, M. P., 1

Bagri, A., 727
Baldi, E., 715
Banks, W. A., 255
Barclay, S. R., 195, 739
Barfield, R. J., 69
Barrera, C. M., 255
Bennett, E. L., 761
Bennett, R. H., 139
Bilitzke, P. J., 599
Billing, A. E., 719
Bitar, M. S., 483
Blanchard, D. C., 551
Blanchard, R. J., 551
Blengio, M., 317
Bodnar, R. J., 153, 371
Bolioli, B., 547
Booth, R. A., 433
Bose, R., 211
Bowes, M. P., 707
Brigham, J., 749
Brioni, J. D., 1
Britton, K. T., 399
Bucherelli, C., 715
Bueno, L., 461
Burger, J., 289
Bylund, D. B., 267

Cade, J. R., 183
Calcagnetti, D. J., 449
Carey, M. P., 719
Castelló, M. E., 547
Castresana, A., 49
Castro, C. A., 159
Chang, A. S., 433
Cheng, M.-F., 739
Cherek, D. R., 139
Chiang, P. K., 377
Chipkin, R. E., 235
Christensen, B. K., 133
Ciancone, M. T., 29
Coen, K. M., 165
Colasanti, B. K., 813
Consolo, S., 99
Corrigall, W. A., 165
Cotton, D. B., 599
Cottrell, G. A., 507
Cottrill, K. L., 295
Craig, C. R., 813
Crowder, W. F., 817, 825

Da Silva, R. C., 767
Dajas, F., 547
Daoust, M., 669
Darmani, N. A., 519
De Miguel, R., 469
Dell'anna, E., 231
Desouza, E. B., 483
Destrade, C., 177
Deutsch, S. I., 263, 663
Dewitte, P., 669
Di Scala, G., 727, 859
Dilsaver, S. C. 23
Dodson, D. L., 625
Domanague, K. R., 455
Drago, F., 445
Dube, S. N., 773
Duffy, R. A., 235
Dukat, M., 361
Dunn, A. J., 643
Durbin, P., 669

Emmanouilidis, E., 49
Erwin, V. G., 275

Farabollini, F., 91
Fargeas, M. J., 461
Fasold, M. B., 255
Felch, L. J., 749
Feldon, J., 309
Fernández-Ruiz, J. J., 469
Ferrari, F., 683
Ferrario, P., 99
Ferreira, M. B. C., 767
Ferretti, C., 317
File, S. E., 695
Fillmore, M. T., 13
Finger, A. V., 159
Franklin, K. B. J., 489
Fratta, W., 497
Fregly, M. J., 183
Fry, J. P., 719
Fujiwara, H., 301
Fukuda, N., 573
Fung, Y. K., 57

Gamzu, E. R., 145
Genovese, R. F., 377
George, F. R., 189
Gessa, G. L., 497
Geter, B., 43
Gewiss, M., 669
Ghi, P., 317
Gibson, J. E. M., 689
Gifford, A. N., 841
Giordano, J., 53
Giuliani, D., 683
Glavin, G. B., 211
Glennon, R. A., 361
Glesson, R. A., 519
Glin, L., 241
Gochfeld, M., 289
Goeders, N. E., 643
Gold, P. E., 295
Gomita, Y., 655
Gong, L., 621
Gonzalez, I., 91
González, M. I., 329, 733
Gorman, A. L., 643
Gormezano, I., 333
Gottesmann, C., 241
Grauffel, C., 603
Grunberg, N. E., 615
Grupp, L. A., 105
Guardiola-Lemaître, B., 405
Gui-Hua, C., 321
Guidi, G., 445
Gulati, K., 7

Hall, J. L., 295
Hall, M. E., 75
Haracz, J. L., 29
Harding, C. F., 195
Hauger, R., 399
Heidbreder, C., 669
Henningfield, J. E., 189
Hernández, M. L., 469
Hicks, L. H., 455
Hienz, R. D., 567
Holtzman, S. G., 449
Hooks, M. S., 203
Hopper, D. L., 707
Hough, L. B., 371
Hudda, M. M., 115
Hudzik, T. J., 215
Hughes, R. A., 349
Hunt, M. A. E., 267
Huston, J. P., 675
Huston-Lyons, D., 755
Hutto, C. W., Jr., 817, 825

Ishida, Y., 539
Izquierdo, I., 767

Janak, P. H., 837, 851
Jaskiw, G. E., 607
Jenden, D. J., 433
Jensen, K., 239
Johnson, K. M., 841
Jones, B. C., 275
Jones, C. H., 121
Jones, G. H., 203
June, H. L., 455
June, P. L., 455
Junien, J.-L., 659
Justice, J. B., Jr., 203

Kádár, T., 665
Kalant, H., 355, 409
Kameyama, T., 171
Kaminska, G., 235
Kantak, K. M., 415
Kastin, A. J., 255
Kato, H., 539
Kautz, M. A., 43
Kawashima, T., 855
Keis, A. F., 483
Kemble, E. D., 581
Kernan, W. J., Jr., 707
Khanna, J. M., 355
Kiefel, J. M., 153
Kim, C. K., 109, 115, 121, 127
Kimball, K. A., 283
Kirkpatrick-Steger, K., 333
Klein, S. A., 189
Kleinrok, Z., 99
Knapp, D. J., 847
Koch, J. E., 371
Kogure, K., 539
Kojima, H., 231
Kolasa, K., 99
Kolonen, S., 701
Koob, G. F., 399
Kornetsky, C., 755
Korpi, E. R., 795
Kostrzewa, R. M., 621
Kulkosky, P. J., 385
Kuzmin, A., 497

Lammintausta, R., 611
Larsen, T., 159
Lau, Y.-S., 57
Lauretz, S. D., 433
Lauria, N., 445
Lawley, S. I., 415
Leduc, P. A., 625
Legrand, E., 669
Lenègre, A., 405
Lepore, M., 489
Leret, M. L., 329, 733
Levin, E. D., 219
Lewis, M. J., 455
Lindqvist, E., 231
Liu, J.-F., 409
Liu, W.-F., 251
Lodge, B. A., 165
Lukacs, L. G., 263
Lummis, G. H., 455
Luthman, J., 231

MacNeil, D. A., 145
Mana, M. J., 109, 121
Mandel, R. J., 343
Männistö, P. T., 795
Martellotta, M. C., 497
Martin, B. R., 519
Martinez, J. A., 461
Martinez, J. L., Jr., 837, 851
Mastropaolo, J., 263, 663
Mauceri, F., 445
McGuirk, J., 801
McLeod, S., 399
McMaster, S. B., 159
McNamara, R. K., 529
McNaughton, N., 475
McQuade, R. D., 235
Medina, J. H., 767
Meehan, S. M., 807
Messier, C., 177
Meyer, M. E., 507
Michael, R. P., 391
Mihic, S. J., 409
Mrabet, O., 177
Mueller, J. L., 429
Mulven, R., 483
Muscat, R., 801

Nader, M. A., 789
Nardo, L., 445
Neill, D. B., 203
Nespor, S. M., 615
Nishimura, H., 425

Norris, D. O., 263
Novitzki, M. R., 263, 663

O'Connor, D. A., 263
O'Connor, T., 415
Oberling, P., 859
Oishi, R., 655
Olson, L., 231
Orikasa, S., 855
Ostrem, J. L., 581
Overstreet, D. H., 23
Owusu,S. E., 483

Parker, L. A., 239, 559
Paul, D., 65
Payan, C., 49
Peck, J. A., 23
Pelloni, F., 683
Perry, B. D., 321
Peters, R. H., 707
Petrie, B. F., 211
Pfaus, J. G., 133
Pickworth, W. B., 189
Pinel, J. P. J., 109, 115, 121, 127, 133
Pinsky, C., 211
Pires, M. L. N., 79
Pleim, E. T., 69
Poenaru, S., 49
Poherecky, L. A., 847
Pomerantz, S. M., 511
Porsolt, R. D., 405
Portaleone, P., 317
Pournaghash, S., 245
Puustinen, P., 701

Quock, R. M., 429

Radcliffe, R. A., 275
Ramos, J. A., 469
Rampello, L., 445
Ramus, S. J., 761
Randall, P. K. 343
Rawleigh, J. M., 581
Ray, A., 7
Rebec, G. V., 29
Reilly, R. T., 295
Reilly, S. M., 289
Reith, M. E. A., 227
Renner, M. J., 625
Rennie, M., 559
Rice, K. M., 433
Riedel, C. A., 851
Riekkinen, M., 611, 637
Riekkinen, P., 611
Riekkinen, P., Jr., 611, 637
Riley, A. L., 43, 245
Roane, D. S., 65
Robertson, J. M., 165
Roch, M., 433
Rocha, B., 859
Rockman, G. E., 689
Rodgers, R. J., 551
Rodríguez de Fonseca, F., 469
Roese, N. R., 127
Rose, J. E., 219
Rosenzweig, M. R., 761
Rouhani, S., 49
Rowland, N. E., 183
Ruggles, J. L., 13
Russell, R. W., 433

Saeki, K., 655
Saito, M., 855
Sandner, G., 727, 859
Sandoval, S. L., 385
Schaefer, G. J., 391
Schally, A. V., 665
Schechter, M. D., 37, 807
Schnur, P., 543
Schomburg, F. M., 53
Schwarting, R. K. W., 675
Seiler, N., 603
Selmeci, G., 227
Serrano, P. A., 761
Shah, G., 355
Shaham, Y., 615
Sharma, K. K., 7
Shephard, R. A., 651
Shepherd, J. K., 551
Shiotani, T., 231
Shiotsuki, N., 79
Shuto, K., 539
Silhol, S., 241
Silva-Filho, A. R., 79
Sirviö, J., 611, 637
Skelton, R. W., 529
Smith, B. R., 259
Smurthwaite, S. T., 43
Solana, R. P., 159
Somani, S. M., 773
Soulairac, A., 49
Standish, N. M., 211
Stevenson, G. W., 245
Stewart, J. M., 75
Stitzer, M. L., 749
Stone, W. S., 295
Stwertka, S. A., 145
Suemaru, K., 655
Sufka, K. J., 53, 349

Tachizawa, H., 231
Tanaka, M., 425
Tassoni, G., 715
Taukulis, H. K., 13
Telegdy, G., 665
Terry, P., 365
Thompson, D. M. 83
Torres, F. K., 587
Toyoshi, T., 171
Tran, G., 49, 669
Trifunovic, R., 501
Tripp, G., 475
Tuominen, K., 795
Tuomisto, J., 701
Turkkan, J. S., 567

Ukai, M., 171

Valerio, C., 445
Van Hartesveldt, C., 507
Vander Linden, S., 333
Vanover, K. E., 789
Verderese, A. G., 145
Vincent, G. P., 145

Wada, T., 573
Wainwright, M., 543
Wamsley, J. K., 267
Wasserman, S. J., 415
Waterman, S. A., 195
Wedlock, P., 651
Weinberger, D. R., 607
Weinberger, S. B., 851
Weiner, I., 309
Weiner, J., 355
Weinstein, M. A., 69
Weiss, S. M., 551
Wenger, G. R., 283
Wettstein, J. G., 659
White, I. M., 29
Wilcox, R. E., 343
Willner, P., 801
Wilson, C. A., 91
Wilson, K. M., 183
Wilson, N. E., 651
Winsauer, P. J., 83
Wirtshafter, D., 501
Witkin, J. M., 377
Witkin, K. M., 377
Wong, D. J., 115
Woolverton, W. L., 321, 789
Wu, P. H., 409

Yanagita, T., 783
Yang, X.-M., 643
Young, R., 361
Yung, A., 115

Zecca, L., 99
Zharkovsky, A., 695
Zimmerberg, B., 587
Zvartau, E., 497